Our Story – ALiA BioTech

The vision of our company founding is to
create an elite POCT platform

React
Respond
Reconnect

About Us

ALiA BioTech is a group of companies that deliver accurate and actionable diagnostic information through our Point-Of-Care Testing (POCT) platform and BioChip, for faster clinical decisions and better economic outcomes for professional and front-line workers.

ALiA BioTech group is formed with our sole purpose of streamlining the way we response to diseases and driving innovations to shape the future of disease diagnostics. ALiA BioTech group has formed a diverse team in Hong Kong, China, France & USA, which is originated from a strong vision for transforming the diagnostic landscape with faster response to disease management. [Sanwa BioTech is a member company of ALiA BioTech group based in Hong Kong. Contact us for collaboration.]

Our Vision & Value

Since our establishment in December 2012, we intend to become a driving force of disease diagnostics and revolutionize healthcare solutions into the future, which is originated from a strong vision for transforming the diagnostic landscape with faster response to disease management.

In order to accomplish our vision, we have developed ALiA^®, an end-to-end Point-of-Care Testing (POCT) platform with digital healthcare management solutions for combating time-critical and life-threatening diseases and outbreaks.

ISO Certification

We are ISO 13485:2016 certified medical device manufacturer since 2018.

ISO 13485:2016 is an internationally recognized quality management system standard for medical device manufacturers. ISO13485 ensures product reliability, regulatory compliance and quality management throughout the life cycle of medical devices, i.e. from product conception to placing the device onto the market, to obsolescence of the device. ISO13485 compliance is a prerequisite for a large number of jurisdictions to place medical devices on the market.